Principal Investigator

Marc Therrien

Intracellular Signalling

Subscribe to the newsletter

Marc Therrien is Professor in the Department of Pathology and Cell Biology of the Faculty of Medicine of the Université de Montréal and Scientific Director of IRIC.

His work on controlling the transcription of genes with Jacques Drouin at the Montreal Clinical Research Institute (IRCM) led to receiving a Ph.D. in Biochemistry at the UdeM In 1993. He then carried out postdoctoral training in molecular genetics with Gerald M. Rubin at the University of California, Berkeley, where he discovered several new components of the RAS-MAPK signalling pathway, the dysregulation of which frequently leads to cancer.

He returned to Montreal in 1999 and held a position as a Principal Investigator at the IRCM until 2003. He then joined the IRIC as one of its founding members and heads the Intracellular Signalling Research Unit. He holds a Canada Research Chair in Intracellular Signalling.

In 2024, Marc Therrien took over as Chief Executive Officer, following the end of Michel Bouvier’s mandate.

Chief Executive Officer, IRIC

Principal Investigator, Intracellular Signalling Research Unit, IRIC

Professor, Department of Pathology and Cell Biology, Faculty of Medicine, Université de Montréal

Research unit on intracellular signalling

Marcelle-Coutu Pavilion, 1306-3 (2306-3)

Phone (office)
(514) 343-7837
Fax
(514) 343-7780
Email
marc.therrien@umontreal.ca
Apply for a M.Sc. or a Ph.D.

Intracellular Signalling

Marc Therrien and his team study the signalling mechanisms involved in cell proliferation and differentiation, more specifically those of the RAS-MAPK intracellular pathway. Dysregulation of these mechanisms is the basis for a large number of cancers.

Discover the research unit View the research team

Research topics

Publications

  • February 22, 2024

    The CNK-HYP scaffolding complex promotes RAF activation by enhancing KSR-MEK interaction.

    Maisonneuve P, Sahmi M, Bergeron-Labrecque F, Ma XI, Queguiner J, Arseneault G, Lefrançois M, Kurinov I, Fronzes R, Sicheri F, Therrien M
    Nat Struct Mol Biol 2024-02-22 ;

  • October 20, 2023

    The human leukemic oncogene MLL-AF4 promotes hyperplastic growth of hematopoietic tissues in Drosophila larvae.

    Johannessen JA, Formica M, Haukeland ALC, Bråthen NR, Al Outa A, Aarsund M, Therrien M, Enserink JM, Knævelsrud H
    iScience 2023-10-20 ;26( 10 ):107726

  • June 15, 2023

    CNK2 promotes cancer cell motility by mediating ARF6 activation downstream of AXL signalling.

    Serwe G, Kachaner D, Gagnon J, Plutoni C, Lajoie D, Duramé E, Sahmi M, Garrido D, Lefrançois M, Arseneault G, Saba-El-Leil MK, Meloche S, Emery G, Therrien M
    Nat Commun 2023-06-15 ;14( 1 ):3560

  • September 1, 2022

    Structural keys unlock RAS-MAPK cellular signalling pathway.

    Lavoie H, Therrien M
    Nature 2022-09-01 ;609( 7926 ):248-249

  • See all publications

Awards and distinctions

  • Canada Research Chair, Tier 1, 2017-2022

  • Canada Research Chair, Tier 2, 2009-2014

  • Canada Research Chair, Tier 2, 2004-2009

  • Scholarship, Canadian Institutes of Health Research, 1999-2004

  • Chercheur-boursier (junior I), FRSQ (declined), 1999-2001

  • Centennial Fellowship, Medical Research Council of Canada, 1996-1998

  • Post-doctoral Fellowship, National Cancer Institute of Canada, 1993-1996

  • Post-doctoral Fellowship, Medical Research Council of Canada (declined), 1993-1994

  • Studentship, Medical Research Council of Canada, 1987-1992

  • Studentship, FCAR (Training funds agency, Quebec), 1986-1987

    • See all awards